newsfilter
← Latest News
Business Wire·

Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Engaging Bispecific Antibodies

Agreement will evaluate Treeline's BCL6 degrader TLN-121 with Roche’s glofitamab-gxbm (COLUMVI®) and mosunetuzumab-axgb (LUNSUMIO®) for the treatment of B-cell lymphomas Preclinical TLN-121 data show enhanced